Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
Provided By GlobeNewswire
Last update: Aug 22, 2025
SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced the appointment of Dan Weng, M.D., to its Board of Directors (the “Board”) effective August 18, 2025.
Read more at globenewswire.com
